Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028

Sagimet updated an investor slide presentation highlighting denifanstat Phase 3 plans for US acne in 2H 2026, clinical data and financial runway.Key Highlights:Original SEC Filing: Sagimet Biosciences Inc. [ SGMT ] - 8-K - Jul. 20, 2026This is an AI-powered summary. It may contain inaccuracies. Con…

Sagimet updated an investor slide presentation highlighting denifanstat Phase 3 plans for US acne in 2H 2026, clinical data and financial runway.

Key Highlights:

Updated presentation will be used in investor meetings and is furnished as Exhibit 99.1 to the 8-K.
Denifanstat met all primary and secondary endpoints in Ascletis Phase 3 acne trial; NDA accepted by China NMPA in Dec 2025.
Sagimet plans to initiate a US Phase 3 denifanstat trial for moderate‑to‑severe acne in 2H 2026, pending FDA consultation; IND open July 2026.
TVB-3567 IND cleared Mar 2025; FIH Phase 1 started June 2025 with Phase 2 targeted for 2H 2026 pending results and regulatory feedback.
$104.5M cash as of 3/31/2026 and $175M Series A offering announced Apr 2026; company expects funding to support operations through 2028 and denifanstat Phase 3 readout.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.